Literature DB >> 24277958

Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.

J Ambroszkiewicz, D Sands, J Gajewska, M Chelchowska, T Laskowska-Klita.   

Abstract

PURPOSE: Some scientific studies show decreased bone mineral density and increased fracture frequency in adult patients with cystic fibrosis (CF). The mechanism for early bone loss in CF patients are multifactorial: chronic pulmonary inflammation, malnutrition, reduced physical activity, delayed pubertal maturation. The aim of this study was to assess bone metabolism markers with special attention paid to osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) balance in CF children.
MATERIAL AND METHODS: The study included 35 children with diagnosed CF and 35 healthy controls aged 5-9 years (median 7.0 years). Serum levels of fat soluble vitamins were measured by chemiluminescence (vitamin D) and HPLC (vitamins A, E) methods. Concentrations of bone metabolism markers were determined by immunoenzymatic assay.
RESULTS: Mean levels of fat soluble vitamins (A, D, E) were lower in patients with CF compared to controls. In CF children we observed a significant (p<0.01) decrease in concentration of bone formation marker (osteocalcin) and similar bone resorption markers (CTX, TRACP5b) in comparison with healthy children. The serum level of OPG was significantly lower (p<0.05) and RANKL nearly 2-fold higher in patients with CF than in the healthy ones. The ratio of OPG to RANKL was about 2-fold lower in children with CF compared to healthy peers (p<0.01).
CONCLUSION: In CF children, an imbalance between bone formation and resorption processes occurs. An increase serum RANKL concentration coexisting with lower levels of OPG may be associated with intensification of bone resorption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277958     DOI: 10.2478/ams-2013-0011

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  7 in total

1.  Reduced bone volumetric density and weak correlation between infection and bone markers in cystic fibrosis adult patients.

Authors:  D Gensburger; S Boutroy; R Chapurlat; R Nove-Josserand; S Roche; M Rabilloud; I Durieu
Journal:  Osteoporos Int       Date:  2016-05-11       Impact factor: 4.507

Review 2.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

Review 3.  Rare causes of osteoporosis.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 4.  Bisphosphonates for osteoporosis in people with cystic fibrosis.

Authors:  Louise S Conwell; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2014-03-14

5.  Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti-fibrosis activity.

Authors:  Yizhou Wang; Timo Michiels; Rita Setroikromo; Ronald van Merkerk; Robbert H Cool; Wim J Quax
Journal:  FEBS J       Date:  2019-05-25       Impact factor: 5.542

Review 6.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

Review 7.  Receptor Specificity Engineering of TNF Superfamily Ligands.

Authors:  Fengzhi Suo; Xinyu Zhou; Rita Setroikromo; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.